Jason Murata

Partner

Contact

Practice Areas

Intellectual Property

Jason Murata draws on over 20 years of experience to address clients' most critical intellectual property challenges. With a strong background in pre-trial, trial, and appellate litigation, he adeptly handles complex IP disputes across a wide range of industries, including pharmaceuticals, biopharmaceuticals, technology, consumer goods, and food products. His extensive litigation background also equips him to navigate critical issues relating to managing clients’ IP risks and freedom to operate. Law360 has recognized Jason as a “Legal Lion” for his skill in arguing before the Federal Circuit on behalf of his clients.

Jason Murata

Partner

San Francisco

Contact

Practice Areas

Intellectual Property

Download PDF Download V-Card

In addition to his active IP practice, Jason is a recognized leader in advancing workplace culture & opportunity within the IP community. Jason has also chaired the Intellectual Property Law Institute at the LGBTQ+ Bar Association’s Lavender Law® Conference and Career Fair on multiple occasions and previously led the AIPLA IP Practice in Japan Committee.

In his pro bono practice, Jason has successfully represented prisoners in cases pertaining to violations of the U.S. Constitution’s Equal Protection Clause.

Experience

Mayne Pharma Int’l Pty Ltd. v. Merck & Co., Inc., No. 15-cv-00438 (D. Del.) (patent infringement action relating to Merck’s Noxafil posaconazole products)
Globus Medical, Inc. v. DePuy Synthes Products, LLC, No. 13-cv-00854 (D. Del.) (defend patent infringement action relating to spinal fusion implants)
Otsuka Pharmaceutical Co., Ltd. v. Zydus Pharmaceuticals USA Inc., Nos. 14-cv-03158-JBS-KMW & 14-cv-07252-JBS-KMW (D.N.J.) (obtained denial of motion for temporary restraining order in patent infringement action relating to generic aripiprazole drug product (Abilify))
Pfizer, Inc. v. Tiger Pharmaceuticals, LLC, No. 14-cv-01501-AJT-TRJ (E.D. Va.); Pfizer, Inc. v. Tiger Pharmaceuticals, LLC, No. 14-cv-08958-GHW (S.D.N.Y.); Johnson Matthey Inc. v. Pfizer, Inc., 2:15-cv-00014-AWA-TEM (E.D. Va.) (obtained dismissal of patent infringement action relating to dofetilide drug product within four months of filing of the action)
Depomed, Inc. v. Actavis Elizabeth LLC, No. 3:12-cv-01358 (D.N.J.) and Appeal No. 14-1828 (Fed. Cir.) (bench trial in patent infringement action relating to generic once-daily gabapentin product)
The Procter & Gamble Co. v. Conopco, Inc., No. 13-CV-00732-TSB (S.D. Ohio) (represented Unilever in patent infringement action relating to antidandruff shampoo products)
Brandeis University v. Unilever United States, Inc., No. 12-cv-01510 (N.D. Ill.) (Posner, J.) (represented Unilever in patent infringement action brought by marketer of SmartBalance products relating to margarines and buttery spreads)
Hospira, Inc. v. Sun Pharmaceutical Industries, Inc., No. 2:10-cv-14514 (BAF/MJH) (E.D. Mich.) (defense of patent infringement action relating to generic dexemdetomidine drug product)
Tyco Healthcare Group LP, et al. v Mutual Pharmaceutical Co., Inc., et al., Civil Action No. 07-cv-1299 (D.N.J.) and Appeal No. 2010-1513 (Fed. Cir.) (obtained summary judgment of invalidity that asserted patent was obvious, which was affirmed by Federal Circuit)
In re Gabapentin Patent Litigation, MDL No. 1384, Master Civil Action No. 00-2931 (D.N.J.) (patent infringement dispute involving gabapentin)
Aventis Pharmaceuticals Inc., et al. v. Sun Pharma Global Inc., et al., Civil Action Nos. 09-cv-00325 & -05179; Civil Action No.: 2:09-cv-5179-JAG (D.N.J.) (patent infringement dispute involving fexofenadine and fexofenadine / pseudoephedrine products)
Roche Palo Alto LLC. v. Endo Pharmaceuticals Inc., Civil Action No. 10-cv-00261-GMS (D. Del.) (patent infringement dispute involving valganciclovir hydrochloride)
United States Gypsum Co. v. Lafarge North America, Inc., Lafarge S.A., et al., Civil Action No. 03-CV-6027 (N.D. Ill. 2003) (theft of confidential, proprietary and trade secret information and patent infringement involving gypsum drywall manufacturing)
Pall Corp. v. Entegris, Inc., Civil Action No. 07-CV-1869 (E.D.N.Y. 2007) (infringement dispute concerning filter media packing and capsule design)
Pall Corp. v. Entegris, Inc., Civil Action No. 05-CV-5894 (E.D.N.Y. 2005) (patent infringement dispute involving filter assembly methods and pre-wet packaging)
Entegris, Inc. v. Pall Corp., Appeal Nos. 2004-1440, 2005-1265, -1266, 2006-1374 (Fed. Cir. 2006) (appeal from preliminary injunction and contempt order in patent infringement dispute concerning filter assembly)
AstraZeneca AB, et al. v. Mutual Pharmaceutical Co., Inc., Appeal No. 04-1100 (Fed. Cir. 2004) (appeal in pharmaceutical case relating to generic extended-release felodipine tablets)
Ciba Specialty Chemicals Corp. v. Zinkan Enterprises Inc., et al., Civil Action No. C2 03 174 (S.D. Ohio 2002) (patent infringement dispute involving treatment of wastewater from coal mining)

Honors

Lawdragon, 500 Leading Litigators in America (2025)
World Intellectual Property Review Leaders (2024)
World Intellectual Property Review Diversity Champion (2024)
American Intellectual Property Law Association, Diversity Champion (2024)

Profiles in Diversity Journal Diverse Lawyers Making a Difference Award Winner (2024)

Profiles in Diversity Journal Asian Leadership Award Winner (2023)
New Leaders in the Law – Connecticut Law Tribune (2014)

Education

JD – Washington University School of Law (2002)
MA, Biology – Washington University (2002)
BS, Biochemistry – McMaster University (1999)

Admissions

California
Connecticut
Illinois
New York
U.S. Court of Appeals for the Federal Circuit
U.S. District Court Northern District of Illinois
U.S. District Court Northern District of California

Quotes

Their knowledge of the industry, law, and implications is deep and thoughtful. The quality of the work...is first-rate.

Chambers USA

Their performance and service is outstanding. They are extremely responsive, give good explanations and keep you up to date.

Chambers USA

Profile

Experience

Mayne Pharma Int’l Pty Ltd. v. Merck & Co., Inc., No. 15-cv-00438 (D. Del.) (patent infringement action relating to Merck’s Noxafil posaconazole products)
Globus Medical, Inc. v. DePuy Synthes Products, LLC, No. 13-cv-00854 (D. Del.) (defend patent infringement action relating to spinal fusion implants)
Otsuka Pharmaceutical Co., Ltd. v. Zydus Pharmaceuticals USA Inc., Nos. 14-cv-03158-JBS-KMW & 14-cv-07252-JBS-KMW (D.N.J.) (obtained denial of motion for temporary restraining order in patent infringement action relating to generic aripiprazole drug product (Abilify))
Pfizer, Inc. v. Tiger Pharmaceuticals, LLC, No. 14-cv-01501-AJT-TRJ (E.D. Va.); Pfizer, Inc. v. Tiger Pharmaceuticals, LLC, No. 14-cv-08958-GHW (S.D.N.Y.); Johnson Matthey Inc. v. Pfizer, Inc., 2:15-cv-00014-AWA-TEM (E.D. Va.) (obtained dismissal of patent infringement action relating to dofetilide drug product within four months of filing of the action)
Depomed, Inc. v. Actavis Elizabeth LLC, No. 3:12-cv-01358 (D.N.J.) and Appeal No. 14-1828 (Fed. Cir.) (bench trial in patent infringement action relating to generic once-daily gabapentin product)
The Procter & Gamble Co. v. Conopco, Inc., No. 13-CV-00732-TSB (S.D. Ohio) (represented Unilever in patent infringement action relating to antidandruff shampoo products)
Brandeis University v. Unilever United States, Inc., No. 12-cv-01510 (N.D. Ill.) (Posner, J.) (represented Unilever in patent infringement action brought by marketer of SmartBalance products relating to margarines and buttery spreads)
Hospira, Inc. v. Sun Pharmaceutical Industries, Inc., No. 2:10-cv-14514 (BAF/MJH) (E.D. Mich.) (defense of patent infringement action relating to generic dexemdetomidine drug product)
Tyco Healthcare Group LP, et al. v Mutual Pharmaceutical Co., Inc., et al., Civil Action No. 07-cv-1299 (D.N.J.) and Appeal No. 2010-1513 (Fed. Cir.) (obtained summary judgment of invalidity that asserted patent was obvious, which was affirmed by Federal Circuit)
In re Gabapentin Patent Litigation, MDL No. 1384, Master Civil Action No. 00-2931 (D.N.J.) (patent infringement dispute involving gabapentin)
Aventis Pharmaceuticals Inc., et al. v. Sun Pharma Global Inc., et al., Civil Action Nos. 09-cv-00325 & -05179; Civil Action No.: 2:09-cv-5179-JAG (D.N.J.) (patent infringement dispute involving fexofenadine and fexofenadine / pseudoephedrine products)
Roche Palo Alto LLC. v. Endo Pharmaceuticals Inc., Civil Action No. 10-cv-00261-GMS (D. Del.) (patent infringement dispute involving valganciclovir hydrochloride)
United States Gypsum Co. v. Lafarge North America, Inc., Lafarge S.A., et al., Civil Action No. 03-CV-6027 (N.D. Ill. 2003) (theft of confidential, proprietary and trade secret information and patent infringement involving gypsum drywall manufacturing)
Pall Corp. v. Entegris, Inc., Civil Action No. 07-CV-1869 (E.D.N.Y. 2007) (infringement dispute concerning filter media packing and capsule design)
Pall Corp. v. Entegris, Inc., Civil Action No. 05-CV-5894 (E.D.N.Y. 2005) (patent infringement dispute involving filter assembly methods and pre-wet packaging)
Entegris, Inc. v. Pall Corp., Appeal Nos. 2004-1440, 2005-1265, -1266, 2006-1374 (Fed. Cir. 2006) (appeal from preliminary injunction and contempt order in patent infringement dispute concerning filter assembly)
AstraZeneca AB, et al. v. Mutual Pharmaceutical Co., Inc., Appeal No. 04-1100 (Fed. Cir. 2004) (appeal in pharmaceutical case relating to generic extended-release felodipine tablets)
Ciba Specialty Chemicals Corp. v. Zinkan Enterprises Inc., et al., Civil Action No. C2 03 174 (S.D. Ohio 2002) (patent infringement dispute involving treatment of wastewater from coal mining)

Honors

Education

Admissions

Their knowledge of the industry, law, and implications is deep and thoughtful. The quality of the work...is first-rate.

Chambers USA

Their knowledge of the industry, law, and implications is deep and thoughtful. The quality of the work...is first-rate.

Chambers USA

News & Insights

View all Insights

April 2, 2025

AIPLA CLE Web Series: Hot Topics in Chemical & Biotech Patent Practice

On April 2, Axinn partner Jason Murata will speak on the American Intellectual Property Law Association's CLE Web Series: Hot Topics in Chemical & Biotech Patent Practice.

Speaking Engagement

November 20, 2024

Jason Murata Named a Profiles in Diversity Journal Diverse Lawyers Making a Difference Award Winner

Profiles in Diversity Journal has named Axinn partner Jason Murata a "Diverse Lawyers Making a Difference Award Winner." This year, 13 individuals were recognized for their commitment to diversifying their respective fields and advancing civil rights in the tech industry and beyond.

Awards & Recognitions

Intellectual Property

October 15, 2024

LSPN North America Fall Conference 2024

On October 15, Axinn partner Jason Murata will speak on the "Intersectionality of Intellectual Property with Licensing and Commercialization" panel at Life Sciences Patent Network's North America Fall Conference, being held October 15-16 in San Francisco.

Speaking Engagement

Intellectual Property

October 8, 2024

ACI 4th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA

On October 8, Axinn partner Jason Murata will speak on the "Key Agencies Overview: Understanding the Jurisdiction and Interplay of the FDA and the USPTO in the Patenting of Drugs, Biologics and Biosimilars" panel at American Conference Institute's Hatch-Waxman and BPCIA Proficiency Series, being held virtually October 8 - 24.

Speaking Engagement

Intellectual Property

News & Insights

Related People

Matthew J. Becker

Intellectual Property Practice Chair

Matt Becker is the Chair of the Intellectual Property practice and has over 25 years of experience trying and litigating a diverse range of patent infringement and trade secret cases. He has tried numerous high-stakes cases to both courts and juries.

Learn more

Brian P. Johnson

Partner

With over 15 years of experience, Brian Johnson is a first chair IP litigation attorney representing clients before the International Trade Commission (ITC) and district courts. He represents clients in litigations involving a wide range of technologies. Brian has had the privilege of representing many of the largest telecommunications companies in the world on many high-stakes competitor disputes. Brian has also argued multiple appeals before the Federal Circuit.

Learn more